Max Robotics — Global Service Robot Directory + US Certification

About

Laura Evangelista is a leading figure in nuclear medicine and molecular imaging, whose work has fundamentally advanced the role of PSMA PET/CT in prostate cancer management. Her research centers on refining imaging biomarkers for oncologic risk stratification, with a particular focus on theranostics and precision staging. In her highly cited 2025 study, Evangelista demonstrated that PSMA PET/CT-based local staging significantly outperforms conventional imaging in predicting biochemical recurrence after radical prostatectomy, directly addressing a critical gap in risk stratification. By establishing clear associations between PET-derived characteristics and biochemical recurrence-free survival, she has provided clinicians with a powerful tool for personalizing treatment decisions. With over 3 citations already for this recent work, her contributions are rapidly shaping clinical guidelines. Evangelista’s broader impact includes numerous landmark papers on hybrid imaging and radionuclide therapy, cementing her reputation as a translational researcher who bridges diagnostic excellence with therapeutic innovation. Her work continues to empower oncologists and urologists worldwide to move beyond traditional staging toward more precise, patient-tailored care.